Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010029/S042

EUFLEXXA (1% SODIUM HYALURONATE)

Ferring Pharmaceuticals, Inc. · Decision date Oct 16, 2025

FDA DECISIONP010029/S042

What did the FDA decide?

FDA records P010029/S042 as a supplement to PMA P010029, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 16, 2025.

FDA approval order statement

Approval for replacement of the autoclave used for sterilization of the filling machine parts.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Oct 16, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P010029/S042
Regulatory pathway
PMA supplement
Product code
MOZ
Decision code
OK30
Decision date
Oct 16, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Acid, hyaluronic, intraarticular.

Product code
MOZ
FDA device class
3

For the original device and its historical approval scope, see PMA P010029. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P010029 · Original PMA

    EUFLEXXA (1% SODIUM HYALURONATE)

  2. P010029/S042 received

    Application receipt date recorded by FDA.

  3. P010029/S042 · FDA decision

    30-Day Notice

  4. P010029/S043 · Related supplement

    EUFLEXXA (1% sodium hyaluronate)

Timeline entries are records held by MedtechLedger for P010029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010029

Product / regulatory recordCompanyPathwayDecision dateSource
Ferring Pharmaceuticals, Inc.PMA approvalDec 3, 2004FDA
Ferring Pharmaceuticals, Inc.PMA supplementSep 2, 2026FDA

Explore the linked device profile

Other records with product code MOZ

Product / regulatory recordCompanyPathwayDecision dateSource
Gel-OneP080020/S056
Seikagaku Corp.PMA supplementSep 4, 2026FDA
SUPARTZ FXP980044/S067
Seikagaku Corp.PMA supplementSep 4, 2026FDA
Anika Therapeutics, Inc.PMA supplementAug 28, 2026FDA
GEL-ONEP080020/S057
Seikagaku Corp.PMA supplementAug 26, 2026FDA
SUPARTZ FXP980044/S068
Seikagaku Corp.PMA supplementAug 26, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ferring Pharmaceuticals, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
100 Interpace Pkwy., Parsippany, NJ, 07054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records